BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

514 related articles for article (PubMed ID: 25819286)

  • 1. Transthyretin V122I amyloidosis with clinical and histological evidence of amyloid neuropathy and myopathy.
    Carr AS; Pelayo-Negro AL; Jaunmuktane Z; Scalco RS; Hutt D; Evans MR; Heally E; Brandner S; Holton J; Blake J; Whelan CJ; Wechalekar AD; Gillmore JD; Hawkins PN; Reilly MM
    Neuromuscul Disord; 2015 Jun; 25(6):511-5. PubMed ID: 25819286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amyloid myopathy: expanding the clinical spectrum of transthyretin amyloidosis-case report and literature review.
    Ungericht M; Wanschitz J; Kroiss AS; Röcken C; Schuetz T; Messner M; Zaruba MM; Loescher WN; Poelzl G
    J Nucl Cardiol; 2023 Aug; 30(4):1420-1426. PubMed ID: 35581484
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic utility of the Perugini grading of 99mTc-DPD scintigraphy in transthyretin (ATTR) amyloidosis and its relationship with skeletal muscle and soft tissue amyloid.
    Hutt DF; Fontana M; Burniston M; Quigley AM; Petrie A; Ross JC; Page J; Martinez-Naharro A; Wechalekar AD; Lachmann HJ; Quarta CC; Rezk T; Mahmood S; Sachchithanantham S; Youngstein T; Whelan CJ; Lane T; Gilbertson JA; Rowczenio D; Hawkins PN; Gillmore JD
    Eur Heart J Cardiovasc Imaging; 2017 Dec; 18(12):1344-1350. PubMed ID: 28159995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transthyretin amyloidosis: Putting myopathy on the map.
    Pinto MV; Milone M; Mauermann ML; Dyck PJB; Alhammad R; McPhail ED; Grogan M; Liewluck T
    Muscle Nerve; 2020 Jan; 61(1):95-100. PubMed ID: 31587306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. (99m)Tc-DPD uptake reflects amyloid fibril composition in hereditary transthyretin amyloidosis.
    Pilebro B; Suhr OB; Näslund U; Westermark P; Lindqvist P; Sundström T
    Ups J Med Sci; 2016; 121(1):17-24. PubMed ID: 26849806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sporadic Cardiac Amyloidosis by Amyloidogenic Transthyretin V122I Variant.
    Nehashi T; Oikawa M; Amami K; Kanno Y; Yokokawa T; Misaka T; Yamada S; Kunii H; Nakazato K; Ishida T; Takeishi Y
    Int Heart J; 2019 Nov; 60(6):1441-1443. PubMed ID: 31666456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis.
    Hutt DF; Quigley AM; Page J; Hall ML; Burniston M; Gopaul D; Lane T; Whelan CJ; Lachmann HJ; Gillmore JD; Hawkins PN; Wechalekar AD
    Eur Heart J Cardiovasc Imaging; 2014 Nov; 15(11):1289-98. PubMed ID: 24939945
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical diversity, diagnosis and treatment of hereditary amyloid neuropathy].
    Sekijima Y
    Rinsho Shinkeigaku; 2014; 54(12):953-6. PubMed ID: 25672679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Low Prevalence of Clinically Apparent Cardiac Amyloidosis Among Carriers of Transthyretin V122I Variant in a Large Electronic Medical Record.
    Agbor-Etang BB; Okafor HE; Farber-Eger EH; Wells QS
    Am J Med; 2021 Feb; 134(2):e98-e100. PubMed ID: 32866461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Noninvasive risk stratification of patients with transthyretin amyloidosis.
    Kristen AV; Scherer K; Buss S; aus dem Siepen F; Haufe S; Bauer R; Hinderhofer K; Giannitsis E; Hardt S; Haberkorn U; Katus HA; Steen H
    JACC Cardiovasc Imaging; 2014 May; 7(5):502-10. PubMed ID: 24726252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An additive destabilising effect of compound T60I and V122I substitutions in ATTRv amyloidosis.
    Prokaeva T; Klimtchuk ES; Feschenko P; Spencer B; Cui H; Burks EJ; Aslebagh R; Muneeruddin K; Shaffer SA; Varghese E; Berk JL; Connors LH
    Amyloid; 2023 Jun; 30(2):141-152. PubMed ID: 36286264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis.
    Rapezzi C; Quarta CC; Guidalotti PL; Pettinato C; Fanti S; Leone O; Ferlini A; Longhi S; Lorenzini M; Reggiani LB; Gagliardi C; Gallo P; Villani C; Salvi F
    JACC Cardiovasc Imaging; 2011 Jun; 4(6):659-70. PubMed ID: 21679902
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The sensitivity of DPD scintigraphy to detect transthyretin cardiac amyloidosis in V30M mutation depends on the phenotypic expression of the disease.
    Azevedo Coutinho MC; Cortez-Dias N; Cantinho G; Gonçalves S; Menezes MN; Guimarães T; Lima da Silva G; Francisco AR; Agostinho J; Santos L; Conceição I; Pinto FJ
    Amyloid; 2020 Sep; 27(3):174-183. PubMed ID: 32482106
    [No Abstract]   [Full Text] [Related]  

  • 14. Description of a large cohort of Caucasian patients with V122I ATTRv amyloidosis: Neurological and cardiological features.
    Gentile L; Di Bella G; Minutoli F; Cucinotta F; Obici L; Mussinelli R; Arimatea I; Russo M; Toscano A; Vita G; Mazzeo A
    J Peripher Nerv Syst; 2020 Sep; 25(3):273-278. PubMed ID: 32395865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation of Quantitative
    Harapoz M; Evans S; Geenty P; Kwok F; Stewart G; Taylor MS; Farlow D; Thomas L
    Heart Lung Circ; 2022 Jun; 31(6):804-814. PubMed ID: 35181228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiac amyloidosis: updates in diagnosis and management.
    Mohty D; Damy T; Cosnay P; Echahidi N; Casset-Senon D; Virot P; Jaccard A
    Arch Cardiovasc Dis; 2013 Oct; 106(10):528-40. PubMed ID: 24070600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction.
    González-López E; Gallego-Delgado M; Guzzo-Merello G; de Haro-Del Moral FJ; Cobo-Marcos M; Robles C; Bornstein B; Salas C; Lara-Pezzi E; Alonso-Pulpon L; Garcia-Pavia P
    Eur Heart J; 2015 Oct; 36(38):2585-94. PubMed ID: 26224076
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of cardiac involvement, extracardiac manifestations and outcomes between homozygote and heterozygote transthyretin p.Val142Ile (V122I) variant in patients with hereditary transthyretin amyloidosis: a cohort study.
    Albenque G; Bézard M; Kharoubi M; Odouard S; Lunati A; Poullot E; Zaroui A; Teiger E; Hittinger L; Audard V; El Karoui K; Funalot B; Fanen P; Damy T; Oghina S
    Amyloid; 2023 Dec; 30(4):407-415. PubMed ID: 37377439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. THAOS - The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis.
    Coelho T; Maurer MS; Suhr OB
    Curr Med Res Opin; 2013 Jan; 29(1):63-76. PubMed ID: 23193944
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Phenotyping of Transthyretin Cardiac Amyloidosis with Bone-Seeking Radiotracers in Heart Failure with Preserved Ejection Fraction.
    Chen W; Ton VK; Dilsizian V
    Curr Cardiol Rep; 2018 Mar; 20(4):23. PubMed ID: 29520480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.